Oxxon Therapeutics Limited (7725872) is a private UK-based company developing innovative, antigen-specific immunotherapies to treat patients with cancer and chronic infectious diseases.
Based in Oxford, UK, Oxford BioMedica (SEA: OXB) is a publicly traded biopharmaceutical company focused on the development of novel gene-based therapeutics particularly in oncology, including therapeutic vaccines, and neurotherapy.
These two companies have entered into an agreement by which Oxxon is to be acquired by Oxford BioMedica: the transaction values Oxxon at GBP16 million, to be satisfied by the issue of Oxford BioMedica shares.
Find more details of the transaction from the press release.
Comment Preview